Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized Study of Cytoreductive Surgery Combined With Niraparib Maintenance in Platinum-sensitive, Secondary Recurrent Ovarian Cancer

NCT03983226 is registered in ClinicalTrials.gov with Shanghai Gynecologic Oncology Group as lead sponsor.

NCT NCT03983226
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03983226 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized Study of Cytoreductive Surgery Combined With Niraparib Maintenance in Platinum-sensitive, Secondary Recurrent Ovarian Cancer
Lead sponsor
Shanghai Gynecologic Oncology Group
Phase
Phase 2
Overall status
Recruiting
Start date
October 18, 2019
Completion date
December 31, 2026
Enrollment
167 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube cancer, ovarian cancer recurrent, primary peritoneal carcinoma